Marco Bua

机构：Imperial College Healthcare NHS Trust, Hammersmith Hospital

发表论文 55 篇 · 总被引 3945 次 · h-index 22

代表论文

• Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib (2010 · Journal of Clinical Oncology · 被引 918)
• Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis (2008 · Journal of Clinical Oncology · 被引 555)
• Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors (2011 · Journal of Clinical Oncology · 被引 478)
• European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor (2008 · Blood · 被引 329)
• Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (2011 · Blood · 被引 321)
• Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression (2008 · Journal of Clinical Oncology · 被引 184)